ANDA 40372, held by Hospira. Promethazine Hydrochloride.
As of Nov 16, 2026, ANDA 40372 (Promethazine Hydrochloride), held by Hospira, was first approved by FDA on Jun 8, 2000, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 8, 2000 | Original application | Approved |
| Promethazine Hydrochloride25MG/ML · injectable;injection | Promethazine Hydrochloride | Discontinued |
| Promethazine Hydrochloride50MG/ML · injectable;injection | Promethazine Hydrochloride | Discontinued |
| Oct 20, 2009 | Supplement 16Labeling | Approved | None posted |
| Feb 25, 2008 | Supplement 14Labeling | Approved | None posted |
| Oct 25, 2007 | Supplement 13Labeling | Approved | None posted |
| Jun 7, 2006 | Supplement 11Labeling | Approved | None posted |
| Mar 13, 2006 | Supplement 10Labeling | Approved | None posted |
| Apr 19, 2004 | Supplement 4Labeling | Approved | None posted |
| Mar 27, 2002 | Supplement 2Manufacturing | Approved | None posted |
| Feb 14, 2001 | Supplement 1Manufacturing | Approved | None posted |
| Jun 8, 2000 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters